Literature DB >> 2028561

Induction of controlled prostatic tissue necrosis by bacille Calmette-Guérin derivatives.

A Morales1, J C Nickel, P N Manley.   

Abstract

Intraprostatic administration of live bacille Calmette-Guérin (BCG) in humans has been found to produce tumor necrosis; unfortunately, the number of severity of complications have made its clinical use prohibitive. Previous studies have shown that soluble and microparticulate components present in the supernatants obtained after centrifugation of a reconstituted BCG preparation exhibit similar immunogenicity to the one shown by live bacteria. The supernatants, however, are not associated with disseminated infection of the progressive regional tissue destruction observed with the use of viable vaccine. Experiments were conducted to determine the effect of intraprostatic injection of BCG and its supernatants. Adult dogs, after positive conversion to protein purified derivative (PPD), were randomly assigned to three groups. Under direct vision and with digital rectal control, intraprostatic injections of various agents were given as follows: group I, normal saline; group II, live BCG; group III, 200 micrograms of BCG supernatants. Two months later the animals were sacrificed, and the prostates removed in toto and submitted for a thorough histological examination. Extensive but variable tissue necrosis was noted in groups II and III. No histological alterations were present in group I. The histological picture of the animals receiving BCG supernatants conclusively demonstrated circumscribed necrosis of the gland. Side effects and complications were present in animals receiving live BCG but conspicuously absent in the ones receiving supernatants. The observed effectiveness and safety of BCG supernatants for intraprostatic administration in an experimental system may lead to a simple, safe, and efficacious therapeutic modality for localized carcinoma of the prostate in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028561     DOI: 10.1007/bf00294019

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  8 in total

1.  MER and other mycobacterial fractions in the immunotherapy of cancer.

Authors:  D W Weiss
Journal:  Med Clin North Am       Date:  1976-05       Impact factor: 5.456

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Treatment of carcinoma of the prostate by interstitial radiation with radio-active gold (Au 198): a preliminary report.

Authors:  R H FLOCKS; H D KERR; H B ELKINS; D CULP
Journal:  J Urol       Date:  1952-08       Impact factor: 7.450

4.  Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.

Authors:  T E Miller; G B Mackaness; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

5.  Immunotherapy of prostatic cancer with Bacillus Calmette-Guérin and purified protein derivative. Preliminary results.

Authors:  C Merrin; T Han; E Klein; G P Murphy
Journal:  Urology       Date:  1973-12       Impact factor: 2.649

6.  Interstitial radiotherapy for localized carcinoma of the prostate.

Authors:  J W Wilson; A Morales; A W Bruce; P Froud
Journal:  Can J Surg       Date:  1983-07       Impact factor: 2.089

7.  Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate.

Authors:  M R Robinson; C C Rigby; R C Pugh; D C Dumonde
Journal:  Br J Urol       Date:  1977-06

8.  BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line.

Authors:  A S Pang; A Morales
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

  8 in total
  1 in total

Review 1.  The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer.

Authors:  Vignesh T Packiam; Shane M Pearce; Gary D Steinberg
Journal:  Ther Adv Urol       Date:  2016-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.